[go: up one dir, main page]

SG11201807252QA - Anti-lag-3 antibodies - Google Patents

Anti-lag-3 antibodies

Info

Publication number
SG11201807252QA
SG11201807252QA SG11201807252QA SG11201807252QA SG11201807252QA SG 11201807252Q A SG11201807252Q A SG 11201807252QA SG 11201807252Q A SG11201807252Q A SG 11201807252QA SG 11201807252Q A SG11201807252Q A SG 11201807252QA SG 11201807252Q A SG11201807252Q A SG 11201807252QA
Authority
SG
Singapore
Prior art keywords
international
agency
research
technology
grove
Prior art date
Application number
SG11201807252QA
Inventor
Cheng-I Wang
Hsueh Ling Janice Oh
Siok Ping Yeo
Chia Yin Lee
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Publication of SG11201807252QA publication Critical patent/SG11201807252QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 111111110111101110101011111 HO 111110111010rn 1111101011111001111101111 MI International Bureau ... .... ..Yjd (10) International Publication Number (43) International Publication Date ..... ...,/ WO 2017/149143 Al 8 September 2017 (08.09.2017) WIP0 I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07K 16/28 (2006.01) kind AO, of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, PCT/EP2017/055060 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, 3 March 2017 (03.03.2017) KP, MD, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (25) Filing Language: English NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (26) Publication Language: English RU, TH, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (30) Priority Data: ZA, ZM, ZW. 10201601719R 4 March 2016 (04.03.2016) SG (84) Designated States (unless otherwise indicated, for every (71) Applicant: AGENCY FOR SCIENCE, TECHNOLOGY kind AND RESEARCH [SG/SG]; 1 Fusionopolis Way #20-10, GM, Connexis, 138632 (SG). TZ, of regional protection available): ARIPO (BW, GH, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (71) Applicant (for LS only): CLEGG, Richard Ian [GB/GB]; TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, City Tower, 40 Basinghall Street, London Greater London DK, EC2V 5DE (GB). LV, SM, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (72) Inventors: WANG, Cheng-I; c/o Agency for Science, GW, KM, ML, MR, NE, SN, TD, TG). — Technology and Research, 8A Biomedical Grove 03-00, Declarations under Rule 4.17: 138648 (SG). OH, Hsueh Ling Janice; c/o Agency for — — — Science Technology and Research, 8A Biomedical Grove — of inventorship (Rule 4.17(iv)) 03-00, 138648 (SG). YEO, Siok Ping; c/o Agency for Sci- Published: ence, Technology and Research, 8A Biomedical Grove 03- = 00, 138648 (SG). LEE, Chia Yin; c/o Agency for Science — with international search report (Art. 21(3)) Technology and Research, 8A Biomedical Grove 03-00, before the expiration of the time limit for amending the 138648 (SG). claims and to be republished in the event of receipt of = = (74) Agents: CLEGG, Richard et al.; Mewburn Ellis LLP, amendments (Rule 48.2(h)) City Tower, 40 Basinghall Street, London Greater London _ with sequence listing part of description (Rule 5.2(a)) EC2V 5DE (GB). = = = = = = = = Il M 7r 11 C:r 7r 11 IN 11 © \" (54) Title: ANTI-LAG-3 ANTIBODIES C ) .,.. (57) : Anti-LAG-3antibodies are disclosed. Also disclosed are compositions comprising such antibodies, and uses and methods using the same.
SG11201807252QA 2016-03-04 2017-03-03 Anti-lag-3 antibodies SG11201807252QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10201601719RA SG10201601719RA (en) 2016-03-04 2016-03-04 Anti-LAG-3 Antibodies
PCT/EP2017/055060 WO2017149143A1 (en) 2016-03-04 2017-03-03 Anti-lag-3 antibodies

Publications (1)

Publication Number Publication Date
SG11201807252QA true SG11201807252QA (en) 2018-09-27

Family

ID=58277259

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201601719RA SG10201601719RA (en) 2016-03-04 2016-03-04 Anti-LAG-3 Antibodies
SG11201807252QA SG11201807252QA (en) 2016-03-04 2017-03-03 Anti-lag-3 antibodies

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201601719RA SG10201601719RA (en) 2016-03-04 2016-03-04 Anti-LAG-3 Antibodies

Country Status (10)

Country Link
US (1) US20190040136A1 (en)
EP (1) EP3423492A1 (en)
JP (1) JP2019517773A (en)
KR (1) KR20180114218A (en)
CN (1) CN109219619A (en)
AU (1) AU2017226965A1 (en)
CA (1) CA3015938A1 (en)
SG (2) SG10201601719RA (en)
TW (1) TW201734042A (en)
WO (1) WO2017149143A1 (en)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI756187B (en) 2015-10-09 2022-03-01 美商再生元醫藥公司 Anti-lag3 antibodies and uses thereof
CA3037380A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
IL313695A (en) 2017-02-10 2024-08-01 Regeneron Pharma Radiolabeled anti-lag3 antibodies for immuno-pet imaging
JP2020522495A (en) 2017-05-30 2020-07-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Composition comprising a combination of anti-LAG-3 antibody, PD-1 pathway inhibitor and immunotherapeutic agent
EP3630179A2 (en) 2017-05-30 2020-04-08 Bristol-Myers Squibb Company Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
KR20240146108A (en) 2017-05-30 2024-10-07 브리스톨-마이어스 스큅 컴퍼니 Treatment of lag-3 positive tumors
JP7269249B2 (en) 2017-11-10 2023-05-08 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ IL2R beta/common gamma chain antibody
EP3768720A4 (en) * 2018-03-20 2022-01-05 Wuxi Biologics Ireland Limited NEW ANTI-LAG-3 ANTIBODY POLYPEPTIDE
CN110343178B (en) * 2018-04-03 2022-07-22 上海开拓者生物医药有限公司 Anti-human LAG-3 monoclonal antibody and application thereof
US20210206848A1 (en) * 2018-05-17 2021-07-08 The Board Of Trustees Of The Leland Stanford Junior University Receptor inhibition by phosphatase recruitment
WO2020023707A1 (en) 2018-07-26 2020-01-30 Bristol-Myers Squibb Company Lag-3 combination therapy for the treatment of cancer
US20210338813A1 (en) 2018-10-19 2021-11-04 Bristol-Myers Squibb Company Combination Therapy for Melanoma
WO2020094836A1 (en) 2018-11-09 2020-05-14 Euchloe Bio Pte. Ltd. Il2rbeta/common gamma chain antibodies
TW202031683A (en) 2018-11-09 2020-09-01 新加坡商優其洛伊生物私人有限公司 Il2rbeta/common gamma chain antibodies
US12187800B2 (en) * 2018-11-22 2025-01-07 Suzhou Kanova Biopharmaceutical Co., Ltd. Anti-B7-H3 antibody
GB201906118D0 (en) * 2019-05-01 2019-06-12 Immutep S A Anti-LAG-3 binding molecules
EP3977132A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Cell localization signature and combination therapy
CN114127315A (en) 2019-05-30 2022-03-01 百时美施贵宝公司 Method of identifying subjects suitable for immunooncology (I-O) therapy
CN114174538A (en) 2019-05-30 2022-03-11 百时美施贵宝公司 Multiple tumor gene signatures suitable for immunooncology therapy
IL267614A (en) * 2019-06-24 2019-09-26 Lotem Michal Nucleic acid agents modulating slamf6 isoforms
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
AU2020350795A1 (en) 2019-09-22 2022-03-31 Bristol-Myers Squibb Company Quantitative spatial profiling for LAG-3 antagonist therapy
WO2021092220A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
WO2021092221A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
EP4054723A1 (en) 2019-11-08 2022-09-14 Bristol-Myers Squibb Company Lag-3 antagonist therapy for melanoma
KR102555328B1 (en) * 2020-02-06 2023-07-17 아주대학교산학협력단 T cell receptor-like antibody to CMV pp65 peptide presented by HLA-A*02 and uses thereof
US20230087600A1 (en) 2020-02-06 2023-03-23 Bristol-Myers Squibb Company Il-10 and uses thereof
JP2023532768A (en) 2020-07-07 2023-07-31 バイオエヌテック エスエー RNA for treatment of HPV-positive cancer
AU2021331476A1 (en) 2020-08-28 2023-05-04 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hepatocellular carcinoma
MX2023002326A (en) 2020-08-31 2023-03-21 Bristol Myers Squibb Co Cell localization signature and immunotherapy.
IL301907A (en) 2020-10-23 2023-06-01 Bristol Myers Squibb Co LAG-3 antagonist therapy for lung cancer
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
CN116514972B (en) * 2020-12-10 2023-10-27 北京东方百泰生物科技股份有限公司 anti-LAG-3 monoclonal antibody, antigen binding fragment thereof and application thereof
TW202245808A (en) 2020-12-21 2022-12-01 德商拜恩迪克公司 Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
MX2023007734A (en) 2020-12-28 2023-08-21 Bristol Myers Squibb Co Antibody compositions and methods of use thereof.
JP2024501029A (en) 2020-12-28 2024-01-10 ブリストル－マイヤーズ スクイブ カンパニー Subcutaneous administration of PD1/PD-L1 antibodies
WO2022165214A1 (en) 2021-01-29 2022-08-04 Board Of Regents, The University Of Texas System Methods of treating cancer with kinase inhibitors
BR112023019847A2 (en) 2021-03-29 2023-11-07 Juno Therapeutics Inc METHODS FOR DOSING AND TREATMENT WITH A COMBINATION OF A CHECKPOINT INHIBITOR THERAPY AND A CAR T CELL THERAPY
EP4337694A1 (en) 2021-05-12 2024-03-20 Dana-Farber Cancer Institute, Inc. Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof
JP2024525758A (en) 2021-07-13 2024-07-12 ビオンテック・ソシエタス・エウロパエア Multispecific binding agents to CD40 and CD137 in combination therapy for cancer - Patents.com
TW202333802A (en) 2021-10-11 2023-09-01 德商拜恩迪克公司 Therapeutic rna for lung cancer
AU2022375806A1 (en) 2021-10-29 2023-12-14 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hematological cancer
MX2024008831A (en) 2022-01-26 2024-07-25 Bristol Myers Squibb Co Combination therapy for hepatocellular carcinoma.
IL314713A (en) 2022-02-25 2024-10-01 Bristol Myers Squibb Co Combination therapy for colorectal carcinoma
WO2023168404A1 (en) 2022-03-04 2023-09-07 Bristol-Myers Squibb Company Methods of treating a tumor
AU2023230110A1 (en) 2022-03-08 2024-10-24 Alentis Therapeutics Ag Use of anti-claudin-1 antibodies to increase t cell availability
KR20240159621A (en) 2022-03-18 2024-11-05 브리스톨-마이어스 스큅 컴퍼니 Method for isolating a polypeptide
EP4531916A1 (en) 2022-06-02 2025-04-09 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
CN115651082A (en) * 2022-11-04 2023-01-31 西北农林科技大学 Preparation method and application of pig LAG3 monoclonal antibody
WO2024116140A1 (en) 2022-12-01 2024-06-06 Medimmune Limited Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies
IL321098A (en) 2022-12-14 2025-07-01 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
AU2023409221A1 (en) 2022-12-21 2025-06-12 Bristol-Myers Squibb Company Combination therapy for lung cancer
US20240299601A1 (en) 2023-02-17 2024-09-12 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-lag3 antibodies for immuno-pet imaging
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
WO2025038763A1 (en) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Ceramic hydroxyapatite chromatography flow through method
US20250179177A1 (en) 2023-10-30 2025-06-05 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025121445A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0615451B1 (en) 1992-05-26 2005-12-07 Immunex Corporation Novel cytokine that binds cd30
ITRM20010408A1 (en) 2001-07-10 2003-01-10 Univ Napoli Federico Ii CYTOTOXIC HUMAN MINI-ANTIBODY FOR CANCER CELLS THAT EXPRESS THE ERBB2 RECEPTOR.
JP4562395B2 (en) 2002-01-09 2010-10-13 メダレックス， インク． Human monoclonal antibody against CD30
SI2511297T1 (en) 2004-02-06 2015-07-31 Morphosys Ag Anti-CD38 human antibodies and uses therefor
WO2006003179A2 (en) 2004-07-01 2006-01-12 Novo Nordisk A/S Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
NZ586780A (en) 2005-03-23 2012-02-24 Genmab As Antibodies against CD38 for treatment of multiple myeloma
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
TWI461436B (en) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd Human CD134 (OX40) human monoclonal antibody and method of making and using same
ES2613957T3 (en) 2006-08-04 2017-05-29 Medimmune Limited Antibodies against ERBB2
EP2087114B1 (en) 2006-11-13 2013-05-29 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Methods of treating cancer using sirna molecules directed against cd24
HUE033472T2 (en) 2007-02-16 2017-12-28 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
US9244059B2 (en) * 2007-04-30 2016-01-26 Immutep Parc Club Orsay Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
EP1987839A1 (en) * 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
WO2009073533A2 (en) 2007-11-30 2009-06-11 Medarex, Inc. Anti-b7h4 monoclonal antibody-drug conjugate and methods of use
AR072999A1 (en) * 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
FI4209510T3 (en) 2008-12-09 2024-03-22 Hoffmann La Roche Anti-pd-l1 antibodies and their use to enhance t-cell function
CN102482701B (en) 2009-09-16 2015-05-13 免疫医疗公司 Class I Anti-CEA antibodies and uses thereof
BR122016002916B8 (en) 2010-03-04 2021-05-25 Macrogenics Inc diabody, nucleic acid molecule, pharmaceutical composition and uses of diabody
EP2576620A1 (en) 2010-05-26 2013-04-10 Regents Of The University Of Minnesota Single -chain variable fragment anti-cd133 antibodies and uses thereof
KR101719118B1 (en) 2010-08-23 2017-03-22 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Anti-ox40 antibodies and methods of using the same
WO2012147713A1 (en) 2011-04-25 2012-11-01 第一三共株式会社 Anti-b7-h3 antibody
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
MX357391B (en) 2011-09-30 2018-07-06 Regeneron Pharma Anti-erbb3 antibodies and uses thereof.
WO2013067492A1 (en) 2011-11-03 2013-05-10 The Trustees Of The University Of Pennsylvania Isolated b7-h4 specific compositions and methods of use thereof
AU2013312211B2 (en) 2012-09-07 2018-03-29 King's College London VISTA modulators for diagnosis and treatment of cancer
WO2014066532A1 (en) 2012-10-23 2014-05-01 Bristol-Myers Squibb Company Combination of anti-kir and anti-ctla-4 antibodies to treat cancer
KR20150100716A (en) 2012-12-19 2015-09-02 앰플리뮨, 인크. Anti-human b7-h4 antibodies and their uses
ES2814962T3 (en) 2013-02-20 2021-03-29 Novartis Ag Efficient targeting of primary human leukemia using anti-CD123 chimeric antigen receptor modified T cells
HUE049957T2 (en) * 2013-03-15 2020-11-30 Glaxosmithkline Ip Dev Ltd Anti-lag-3 binding proteins
US9790282B2 (en) 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
BR122023024195A2 (en) 2013-09-20 2023-12-26 Bristol-Myers Squibb Company USES OF ANTI-LAG-3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
CN119775416A (en) 2013-12-24 2025-04-08 杨森制药公司 Anti-VISTA antibodies and fragments

Also Published As

Publication number Publication date
CN109219619A (en) 2019-01-15
US20190040136A1 (en) 2019-02-07
KR20180114218A (en) 2018-10-17
JP2019517773A (en) 2019-06-27
EP3423492A1 (en) 2019-01-09
AU2017226965A1 (en) 2018-10-11
CA3015938A1 (en) 2017-09-08
TW201734042A (en) 2017-10-01
WO2017149143A1 (en) 2017-09-08
SG10201601719RA (en) 2017-10-30

Similar Documents

Publication Publication Date Title
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201809857TA (en) Anti-CTLA-4 Antibodies
SG11201909949XA (en) Targeted immunotolerance
SG11201909322VA (en) Treatment of asthma with anti-tslp antibody
SG11201805950UA (en) Self-assembled nanostructures and separation membranes comprising aquaporin water channels and methods of making and using them
SG11201811184UA (en) Lag -3 binding members
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201804836RA (en) Treatment of fibrosis
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201805493YA (en) Binding members with altered diversity scaffold domains
SG11201805570WA (en) Systems and methods for long term transdermal administration
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201806845VA (en) Moisturizing compositions and uses thereof
SG11201901959YA (en) Modified stem cell memory t cells, methods of making and methods of using same
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201810430WA (en) Heater assembly for an aerosol-generating system
SG11201900634VA (en) Chimeric antigen receptor
SG11201903012RA (en) Anti-c1s antibodies and methods of use thereof
SG11201808525UA (en) Anti-complement factor bb antibodies and uses thereof
SG11201809531SA (en) BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF
SG11201805001UA (en) Method of treating influenza a
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201809594WA (en) Nicotine particles and compositions
SG11201903329WA (en) Method for preparing electrocompetent yeast cells, and method for using said cells
SG11201809474TA (en) Compositions and methods for bioengineered tissues